Gilead Sciences said on Monday a late-stage study showed that its drug Trodelvy used in combination with Merck's ...

The drug's safety profile was consistent with that found in prior studies, with no new safety signals identified.

The FDA is currently reviewing Merck’s sBLA for Keytruda in head and neck cancer, with a target action date of June 23.

Pembrolizumab combo before/after surgery and radiation significantly improved event-free survival in resectable advanced head ...

Despite the failures, ALX Oncology remains hopeful about evorpacept and is focusing on combination trials with other ...

We believe investors with a long-term horizon should stay invested in MRK stock, while short-term investors may exit the stock.

Ten (10) patients have achieved an objective response (5 confirmed) when treated with MDNA11 alone or in combination with KEYTRUDA® (pembrolizumab) – all responders had advanced and/or metastatic canc ...

With ivonescimab’s data coming solely from China, its prospects in the U.S., where Summit owns the rights, remain up in the ...

As an unplanned overall survival analysis of ivonescimab’s Keytruda head-to-head trial rocked the PD- (L)1xVEGF world, Akeso ...

In advanced head and neck squamous cell carcinoma, evorpacept and Keytruda didn’t meet the primary endpoints of the ASPEN-03 ...

Akeso has shared for the first time overall survival data from a high-profile Keytruda head-to-head trial for its PD-1xVEGF ...

Market volatility has led to compelling dividend opportunities, and Merck and Schlumberger offer great value at low PE ratios ...